LMC Healthcare
Hospital
Location:
Toronto,
Canada (CA)
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial (2026)
Mulvagh SL, Inzucchi SE, Marx N, Poulter NR, Deanfield JE, Pop-Busui R, Emerson SS, et al.
Journal article
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial (2025)
Marx N, Deanfield JE, Mann JF, Arechavaleta R, Bain SC, Bajaj HS, Bayer Tanggaard K, et al.
Journal article